EANS-Adhoc: Marseille-Kliniken AG: Result improvement in business year 2011/2012
--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
01.10.2012
Hamburg, 01 October 2012 - Marseille-Kliniken AG (Prime Standard, ISIN
DE0007783003, MKA) has achieved an increase in results in business year
2011/2012 (1 July - 30 June). Revenues increased to EUR 195.1 million. EBIT
increased to EUR 10.9 million, earnings per share moved to EUR 0.45 (previous
year EUR 0.20). Occupancy rate rose to 88.9%.
The core business "care for elderly and patients" in the segments inpatient and
outpatient still shows high vacancies, although total occupancy rate has
increased by almost 2% in the last business year. At this point the company
still has significant potential which has not been made accessible yet.
The general skills shortage in Germany hinders the company from rapidly
improving capacity utilization in its facilities. Internal reorganization
including decentralization of the operational business is not completed.
With the appointment of Dieter Wopen as new member of the management board
starting on 15 November 2012 the company shall insofar "gain speed". The
contract with chairman Michael Thanheiser was prematurely prolonged until 31
March 2017.
The annual report 2011/2012 will be published on Monday, 08 October 2012.
end of ad-hoc-announcement
================================================================================
About Marseille-Kliniken AG:
Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with its 57
residential care facilities, three residential units for assisted living and
about 4,700 employees is a market leading listed company on health care in
Germany. The business model is significantly influenced by the demographic
development. Therefore Marseille-Kliniken AG has a secured future. Short-term
economic fluctuations on the other hand exert only a minor influence. As a
consistently modern company with strong focus on quality, the private enterprise
is in a good position within a competitive environment primarily characterized
by regionally active charities.
Further inquiry note:
Hillermann Consulting
Jan Pahl
Investor Relations for Marseille-Kliniken AG
Poststraße 14-16
20354 Hamburg
Germany
Tel.: +49 - (0)40 / 3202791-0
www.marseille-kliniken.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: Marseille-Kliniken AG
Alte Jakobstraße 79/80
D-10179 Berlin
phone: +49 (0)30 246 32-400
FAX: +49 (0)30 246 32-401
mail: info@marseille-kliniken.de
WWW: http://www.marseille-kliniken.de
sector: Pharmaceuticals
ISIN: DE0007783003
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
Hamburg, regulated dealing/prime standard: Frankfurt
language: English